These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22847974)

  • 21. In-vivo impaired T helper 1 cell development in submandibular lymph nodes due to IL-12 deficiency following antigen injection into the anterior chamber of the eye.
    Perez VL; Biuckians AJ; Streilein JW
    Ocul Immunol Inflamm; 2000 Mar; 8(1):9-24. PubMed ID: 10806431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone marrow is a preferential homing site for autoreactive T-cells in type 1 diabetes.
    Li R; Perez N; Karumuthil-Melethil S; Vasu C
    Diabetes; 2007 Sep; 56(9):2251-9. PubMed ID: 17596402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced engraftment of human cells in RAG2/gammac double-knockout mice after treatment with CL2MDP liposomes.
    Rozemuller H; Knaän-Shanzer S; Hagenbeek A; van Bloois L; Storm G; Martens AC
    Exp Hematol; 2004 Nov; 32(11):1118-25. PubMed ID: 15539091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
    Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy.
    Liu S; Riley J; Rosenberg S; Parkhurst M
    J Immunother; 2006; 29(3):284-93. PubMed ID: 16699371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphoid hyperplasia, CD45RBhigh to CD45RBlow T-cell imbalance, and suppression of Type I diabetes mellitus result from TNF blockade in NOD-->NOD-scid adoptive T cell transfer.
    Brown GR; Silva MD; Thompson PA; Beutler B
    Diabetologia; 1998 Dec; 41(12):1502-10. PubMed ID: 9867218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy.
    Korbelik M; Krosl G; Krosl J; Dougherty GJ
    Cancer Res; 1996 Dec; 56(24):5647-52. PubMed ID: 8971170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients.
    Aranda R; Sydora BC; McAllister PL; Binder SW; Yang HY; Targan SR; Kronenberg M
    J Immunol; 1997 Apr; 158(7):3464-73. PubMed ID: 9120308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient xenoengraftment in severe immunodeficient NOD/Shi-scid IL2rγnull mice is attributed to a lack of CD11c+B220+CD122+ cells.
    Ito R; Katano I; Ida-Tanaka M; Kamisako T; Kawai K; Suemizu H; Aiso S; Ito M
    J Immunol; 2012 Nov; 189(9):4313-20. PubMed ID: 23018460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histological assessment of the sclerotic graft-versus-host response in the humanized RAG2-/-γc-/- mouse model.
    Hogenes MC; van Dorp S; van Kuik J; Monteiro FR; ter Hoeve N; van Dijk MR; Martens AC; de Weger RA
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1023-35. PubMed ID: 22579931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved engraftment of human cord blood stem cells in NOD/LtSz-scid/scid mice after irradiation or multiple-day injections into unirradiated recipients.
    Lowry PA; Shultz LD; Greiner DL; Hesselton RM; Kittler EL; Tiarks CY; Rao SS; Reilly J; Leif JH; Ramshaw H; Stewart FM; Quesenberry PJ
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):15-23. PubMed ID: 9078350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.
    Cheadle EJ; Hawkins RE; Batha H; O'Neill AL; Dovedi SJ; Gilham DE
    J Immunol; 2010 Feb; 184(4):1885-96. PubMed ID: 20089697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
    Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
    J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.
    Galvan DL; O'Neil RT; Foster AE; Huye L; Bear A; Rooney CM; Wilson MH
    PLoS One; 2015; 10(10):e0140744. PubMed ID: 26473608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice.
    Shultz LD; Schweitzer PA; Christianson SW; Gott B; Schweitzer IB; Tennent B; McKenna S; Mobraaten L; Rajan TV; Greiner DL
    J Immunol; 1995 Jan; 154(1):180-91. PubMed ID: 7995938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved multilineage human hematopoietic reconstitution and function in NSGS mice.
    Wunderlich M; Chou FS; Sexton C; Presicce P; Chougnet CA; Aliberti J; Mulloy JC
    PLoS One; 2018; 13(12):e0209034. PubMed ID: 30540841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.
    Ali R; Babad J; Follenzi A; Gebe JA; Brehm MA; Nepom GT; Shultz LD; Greiner DL; DiLorenzo TP
    Immunology; 2016 Aug; 148(4):339-51. PubMed ID: 27124592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human B cell development and antibody production in humanized NOD/SCID/IL-2Rγ(null) (NSG) mice conditioned by busulfan.
    Choi B; Chun E; Kim M; Kim ST; Yoon K; Lee KY; Kim SJ
    J Clin Immunol; 2011 Apr; 31(2):253-64. PubMed ID: 20981478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a humanized mouse model to study the role of macrophages in allograft injury.
    Kirkiles-Smith NC; Harding MJ; Shepherd BR; Fader SA; Yi T; Wang Y; McNiff JM; Snyder EL; Lorber MI; Tellides G; Pober JS
    Transplantation; 2009 Jan; 87(2):189-97. PubMed ID: 19155972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating Human Immune Responses for Vaccine Development in a Novel Human Spleen Cell-Engrafted NOD-SCID-IL2rγNull Mouse Model.
    Ghosn S; Chamat S; Prieur E; Stephan A; Druilhe P; Bouharoun-Tayoun H
    Front Immunol; 2018; 9():601. PubMed ID: 29628927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.